Company: RGNT
Filing Date: 2025-09-09
Form Type: F-1/A
Source: 0001213900-25-085690
Chunk: 7

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-09
Form: F-1/A
Chunk 7
---
 debt will become immediately due and payable upon an event
of default (as defined in the December 2024 Loan Agreement), which shall be deemed to have occurred upon certain circumstances as detailed
in the December 2024 Loan Agreement. On March 31, 2025, we and our Chief Executive Officer entered an amendment to the December 2024
Loan Agreement to extend the maturity date until the earlier of August 31, 2025, or the consummation of an IPO. On July 1, 2025, we entered
into an amendment to the December 2024 Loan Agreement such that our Chief Executive Officer shall be granted warrants to purchase up
to 55,224 Ordinary Shares following the consummation of this public offering.

In April 2025, we entered
into bridge loan agreements, or the 2025 Loan Agreements, pursuant to which we obtained a bridge loans in the aggregate amount of $200,000
from certain lenders, including certain related parties. The loans pursuant to the 2025 Loan Agreements bear interest at a rate of 8%
per annum until maturity. Pursuant to the terms of the 2025 Loan Agreements, we also agreed to pay the lenders an additional risk premium
equal to 50% of their respective loan amount. The loans under the 2025 Loan Agreements mature upon the earlier of August 31, 2025 or
the date of consummation of a Qualified IPO. Furthermore, upon the occurrence of a Qualified IPO, the Bridge Loan lenders, shall be granted
warrants to purchase such number of Ordinary Shares equal to 92,309 Ordinary Shares following the consummation of this offering.

The sales of the above securities
were deemed to be exempt from registration under the Securities Act because they were made outside of the United States of America to
certain non-U.S. individuals or entities pursuant to Regulation S or, in reliance upon the exemption from registration provided under
Section 4(a)(2) of the Securities Act and the regulations promulgated thereunder.

We claimed exemption from
registration under the Securities Act for the option grants described above under Section 4(a)(2), Regulation S, or under Rule 701
of the Securities Act as transactions pursuant to written compensatory plans or pursuant to a written contract relating to compensation.

No underwriters were employed
in connection with the securities issuances set forth in this Item.

<div align='center'>II-3</div>

Item 8. Exhib